EGFR and cancer: On the other hand, WFDC2 has been identified as a prominent biomarker in various cancers, including lung, ovarian, and prostate cancers, with roles in tumor metastasis and prognosis due to its interaction with EGFR and its ability to modulate cancer cell migration (Xiong et al., 2020; Nagy et al., 2014; James et al., 2018).